Damora Therapeutics is trading 6.27% up in pre-market at $31.00, versus the September 8 close of $29.17, with no major company-specific announcement dated September 9, 2026 identified to explain the gain.
- The latest company release, dated September 3, concerned inducement grants for three employees and is unlikely to be a fresh catalyst.
- Broader healthcare and major U.S. indexes are lower, so neither sector nor market direction clearly explains the move.